RMD$215.15

ResMed’s network effects are real, but they are indirect rather than consumer-social in nature. The value comes from a growing installed base of connected sleep and breathing devices feeding AirView, which improves remote monitoring, reporting, and clinical workflow for physicians and home-care providers. As more patients and clinicians use the system, the data set gets richer and the platform becomes more useful for compliance, treatment tracking, and future product development. That creates a reinforcing loop that encourages adoption of the integrated stack. The effect is meaningful, though not invulnerable, because customers can still multi-home across software and device vendors if the workflow friction is low enough over time, limiting the score from reaching the top tier.

Switching costs are one of ResMed’s strongest moats. Patients typically enter therapy through a physician-prescribed setup, then remain tied to a specific mask, tubing, device, and reimbursement path for years. The company’s resupply programs further reduce churn by automatically replenishing consumables on a schedule, while AirView and other digital tools embed ResMed into provider documentation, compliance, and remote monitoring routines. A switch would require retraining, new equipment, new fitting, and often new administrative handling. The cost is not purely financial; it is also clinical and operational. That said, the therapy itself is not permanently locked, so switching is feasible over a device cycle, which keeps the rating below a perfect score.

ResMed’s intangible assets are meaningful and durable, led by a strong brand with sleep physicians, durable medical equipment channels, and patients who associate it with reliable therapy. The company also holds a broad patent portfolio and a large base of granted and pending designs that protect elements of device functionality and form factor. Regulatory know-how, clinical evidence, and accumulated customer relationships add to the protection. These assets support pricing discipline and reinforce the company’s ability to maintain premium positioning in consumables and software. The weakness is that patents eventually expire and the brand is not absolute; rivals can still compete with adequate engineering and distribution. Still, the combined effect is substantial and hard to replicate quickly.

ResMed enjoys real cost advantages from scale, but they are moderate rather than overwhelming. With more than $5 billion in annual revenue, it can spread manufacturing, regulatory, software, and administrative costs across a very large base of devices and consumables. Its bargaining position with suppliers, logistics providers, and contract manufacturers is materially better than smaller competitors, helping contain input inflation and improve service reliability. The recurring resupply model also supports better utilization and margin stability. Evidence of operating leverage suggests that scale is still converting into earnings power. However, this is not a permanently unassailable cost position, because well-funded rivals can still invest in comparable manufacturing and supply-chain capabilities over time.

ResMed operates in a market with limited economically viable competitors, especially in sleep-disordered breathing and connected respiratory devices. Its market share is high, while Philips’ long regulatory issues have reduced competitive intensity and made it harder for challengers to gain shelf space, physician trust, and reimbursement traction. The industry also has high entry hurdles: regulatory approvals, clinical validation, distribution relationships, and patient safety concerns all slow new entrants. This is not a true natural monopoly, because several competitors remain active and the software-adjacent businesses are more fragmented. Even so, the structure supports efficient scale, particularly in the core device-and-consumables layer, and helps explain why incumbent share can remain sticky for long periods.